UNLABELLED: It is unknown whether transforming growth factor beta1 (TGF-beta1) signaling uniformly participates in fibrogenic chronic liver diseases, irrespective of the underlying origin, or if other cytokines such as interleukin (IL)-13 share in fibrogenesis (e.g., due to regulatory effects on type I pro-collagen expression). TGF-beta1 signaling events were scored in 396 liver tissue samples from patients with diverse chronic liver diseases, including hepatitis B virus (HBV), hepatitis C virus (HCV), Schistosoma japonicum infection, and steatosis/steatohepatitis. Phospho-Smad2 staining correlated significantly with fibrotic stage in patients with HBV infection (n = 112, P < 0.001) and steatosis/steatohepatitis (n = 120, P < 0.01), but not in patients with HCV infection (n = 77, P > 0.05). In tissue with HBx protein expression, phospho-Smad2 was detectable, suggesting a functional link between viral protein expression and TGF-beta1 signaling. For IL-13, immunostaining correlated with fibrotic stage in patients with HCV infection and steatosis/steatohepatitis. IL-13 protein was more abundant in liver tissue lysates from three HCV patients compared with controls, as were IL-13 serum levels in 68 patients with chronic HCV infection compared with 20 healthy volunteers (72.87 +/- 26.38 versus 45.41 +/- 3.73, P < 0.001). Immunohistochemistry results suggest that IL-13-mediated liver fibrogenesis may take place in the absence of phospho-signal transducer and activator of transcription protein 6 signaling. In a subgroup of patients with advanced liver fibrosis (stage > or =3), neither TGF-beta nor IL-13 signaling was detectable. CONCLUSION: Depending on the cause of liver damage, a predominance of TGF-beta or IL-13 signaling is found. TGF-beta1 predominance is detected in HBV-related liver fibrogenesis and IL-13 predominance in chronic HCV infection. In some instances, the underlying fibrogenic mediator remains enigmatic.
UNLABELLED: It is unknown whether transforming growth factor beta1 (TGF-beta1) signaling uniformly participates in fibrogenic chronic liver diseases, irrespective of the underlying origin, or if other cytokines such as interleukin (IL)-13 share in fibrogenesis (e.g., due to regulatory effects on type I pro-collagen expression). TGF-beta1 signaling events were scored in 396 liver tissue samples from patients with diverse chronic liver diseases, including hepatitis B virus (HBV), hepatitis C virus (HCV), Schistosoma japonicum infection, and steatosis/steatohepatitis. Phospho-Smad2 staining correlated significantly with fibrotic stage in patients with HBV infection (n = 112, P < 0.001) and steatosis/steatohepatitis (n = 120, P < 0.01), but not in patients with HCV infection (n = 77, P > 0.05). In tissue with HBx protein expression, phospho-Smad2 was detectable, suggesting a functional link between viral protein expression and TGF-beta1 signaling. For IL-13, immunostaining correlated with fibrotic stage in patients with HCV infection and steatosis/steatohepatitis. IL-13 protein was more abundant in liver tissue lysates from three HCVpatients compared with controls, as were IL-13 serum levels in 68 patients with chronic HCV infection compared with 20 healthy volunteers (72.87 +/- 26.38 versus 45.41 +/- 3.73, P < 0.001). Immunohistochemistry results suggest that IL-13-mediated liver fibrogenesis may take place in the absence of phospho-signal transducer and activator of transcription protein 6 signaling. In a subgroup of patients with advanced liver fibrosis (stage > or =3), neither TGF-beta nor IL-13 signaling was detectable. CONCLUSION: Depending on the cause of liver damage, a predominance of TGF-beta or IL-13 signaling is found. TGF-beta1 predominance is detected in HBV-related liver fibrogenesis and IL-13 predominance in chronic HCV infection. In some instances, the underlying fibrogenic mediator remains enigmatic.
Authors: Elvira Alonso-Merino; Rosa Martín Orozco; Lidia Ruíz-Llorente; Olaia A Martínez-Iglesias; Juan Pedro Velasco-Martín; Ana Montero-Pedrazuela; Luisa Fanjul-Rodríguez; Constanza Contreras-Jurado; Javier Regadera; Ana Aranda Journal: Proc Natl Acad Sci U S A Date: 2016-05-31 Impact factor: 11.205
Authors: Yan Liu; Heng Liu; Christoph Meyer; Jun Li; Silvio Nadalin; Alfred Königsrainer; Honglei Weng; Steven Dooley; Peter ten Dijke Journal: J Biol Chem Date: 2013-09-04 Impact factor: 5.157
Authors: Cheng Zhu; Eva Sauter; Anja Schreiter; Claudia R C van Roeyen; Tammo Ostendorf; Jürgen Floege; Florian Gembardt; Christian P Hugo; Berend Isermann; Jonathan A Lindquist; Peter R Mertens Journal: J Am Soc Nephrol Date: 2016-05-05 Impact factor: 10.121
Authors: Zhe Shen; Yan Liu; Bedair Dewidar; Junhao Hu; Ogyi Park; Teng Feng; Chengfu Xu; Chaohui Yu; Qi Li; Christoph Meyer; Iryna Ilkavets; Alexandra Müller; Carolin Stump-Guthier; Stefan Munker; Roman Liebe; Vincent Zimmer; Frank Lammert; Peter R Mertens; Hai Li; Peter Ten Dijke; Hellmut G Augustin; Jun Li; Bin Gao; Matthias P Ebert; Steven Dooley; Youming Li; Hong-Lei Weng Journal: Am J Pathol Date: 2016-05-10 Impact factor: 4.307
Authors: Qunfeng Wu; Liya Pi; Thu Le Trinh; Chaohui Zuo; Man Xia; Yu Jiao; Zhouhua Hou; Sung Jo; William Puszyk; Kien Pham; David R Nelson; Keith Robertson; David Ostrov; Pranela Rameshwar; Chang Qing Xia; Chen Liu Journal: Mol Ther Date: 2017-08-10 Impact factor: 11.454
Authors: Hamid Mattoo; Vinay S Mahajan; Takashi Maehara; Vikram Deshpande; Emanuel Della-Torre; Zachary S Wallace; Maria Kulikova; Jefte M Drijvers; Joe Daccache; Mollie N Carruthers; Flavia V Castelino; James R Stone; John H Stone; Shiv Pillai Journal: J Allergy Clin Immunol Date: 2016-03-11 Impact factor: 10.793